Optic Neuritis Treatment Market Analysis

  • Report ID: 4174
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Optic Neuritis Treatment Market Analysis

End-User (Ambulatory Surgery Centers, Clinics, Hospitals)

The hospital segment in the optic neuritis treatment market is estimated to gain a robust revenue share in the coming years owing to the availability of medical device testing, medical professionals in a single place, and a notable patient pool. In addition, hospitals have specialized departments which have the expertise and better resources to provide quality care for optic neuritis patients. Advanced diagnostic tools and around-the-clock medical professionals are also easily available on hospital premises, aiding in the accurate and timely diagnosis of optic neuritis.

Treatment Type (Surgery, Pharmacological)

Optic neuritis treatment market from the pharmacological segment is set to garner a notable share in the near future since pharmacological treatments such as the usage of steroid medications are used to lessen inflammation in the optic nerve and hasten the healing of ocular neuritis. The treatment also includes corticosteroid drugs used to treat optic neuritis, which has proved its efficiency for decades. For instance, for improving visual outcomes in optic neuritis, the use of an oral high-dose corticosteroid is just as effective as a high-dose intravenous corticosteroid. Besides this, pharmacological treatment includes disease-modifying therapies that are widely used to treat optic neuritis cases associated with multiple sclerosis.

Our in-depth analysis of the global market includes the following segments:

Treatment Type

  • Surgery
  • Pharmacological

Indication

  • Optic Neuritis & Neuropathy
  • Optic Atrophy
  • Glaucoma
  • Congenital

End-User

  • Ambulatory Surgery Centers
  • Clinics
  • Hospitals
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4174
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of optic neuritis treatment is assessed at USD 243.59 Million.

The optic neuritis treatment market size was over USD 232.1 Million in 2023 and is poised to reach USD 465.54 Million by the end of 2036, growing at around 5.5% CAGR during the forecast period i.e., between 2024-2036. Rising incidences of bacterial infections across the globe and the significant increment in global geriatric population are the major factors driving the growth of the market.

North America is predicted to account for the largest share of 35% by 2036, impelled by higher adoption of steroids in the region.

Santen Pharmaceutical Co., Ltd., Mallinckrodt plc, AbbVie Inc., Novartis AG, Sanofi-aventis Groupe, AdvoCare International, Hikma Pharmaceuticals PLC, Henry Schein, Inc., Fresenius Kabi USA, Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample